Zynex (ZYXI) to Release Quarterly Earnings on Wednesday

Zynex (NASDAQ:ZYXI) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect Zynex to post earnings of ($0.20) per share and revenue of $27.38 million for the quarter.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.09). Zynex had a negative return on equity of 23.70% and a negative net margin of 4.30%. The business had revenue of $26.58 million for the quarter, compared to analysts’ expectations of $30.83 million. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zynex Price Performance

ZYXI stock opened at $2.28 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.46 and a quick ratio of 2.63. Zynex has a one year low of $1.66 and a one year high of $10.62. The stock has a market cap of $68.95 million, a PE ratio of -9.50 and a beta of 0.83. The firm has a 50 day simple moving average of $2.32 and a two-hundred day simple moving average of $4.28.

Wall Street Analyst Weigh In

ZYXI has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Zynex in a research report on Monday, June 30th. Royal Bank Of Canada cut their price objective on Zynex from $4.00 to $3.00 and set a “sector perform” rating for the company in a report on Tuesday.

Institutional Investors Weigh In On Zynex

A hedge fund recently raised its stake in Zynex stock. Jane Street Group LLC grew its stake in Zynex Inc. (NASDAQ:ZYXI) by 239.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 53,377 shares of the company’s stock after purchasing an additional 37,673 shares during the quarter. Jane Street Group LLC owned about 0.18% of Zynex worth $117,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.